Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
1996

Study on Chemotherapy for Small-Cell Lung Cancer

Sample size: 25 publication Evidence: moderate

Author Information

Author(s): A Ardizzoni, MC Pennucci, M Danova, C Viscoli, GL Mariani, G Giorgi, M Venturini, C Mereu, T Scolaro, R Rosso

Primary Institution: Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Hypothesis

Can the dose intensity of an accelerated chemotherapy regimen for small-cell lung cancer be increased further using granulocyte colony-stimulating factor?

Conclusion

The study found that it is possible to increase the dose intensity of chemotherapy for small-cell lung cancer using a combination of dose escalation and schedule acceleration.

Supporting Evidence

  • All patients at the first dose level completed three or more cycles without dose-limiting toxicity.
  • At the second dose level, three out of five patients experienced dose-limiting toxicity.
  • With the addition of prophylactic antibiotics, the second dose level was considered feasible.

Takeaway

Doctors tested a new way to give chemotherapy to lung cancer patients to make it stronger, and it worked better than before.

Methodology

Patients received escalating doses of chemotherapy drugs along with granulocyte colony-stimulating factor and were monitored for dose-limiting toxicities.

Limitations

The small sample size limits the generalizability of the findings.

Participant Demographics

Median age was 58 years, with 21 males and 4 females.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication